Introduction: Tigecycline is a relatively new antibiotic that have very limited valid indications. When no other alternative is available, this drug is widely used off label with promising results. The objective of this study is to summarize the different off label uses of tigecycline so that we can decide when and how to prescribe it in the absence of guidelines.
Material And Methods: This study a revue of the literature collecting all the articles concerning the off label uses of tigecycline.
Results: Tigecycline was widely prescribed, off label, to treat infections with controversial results. Randomised clinical trials were conducted to evaluate its use to treat pneumonia. The results for this indication have a respectable level of evidence. For the other indications, the data collected was insufficient to support tigecycline prescription. In fact, different protocols were used which makes it hard to evaluate the efficacy and to conclude to the best treatment regimen. A tendency to prescribe high doses of the molecule was noted in different studies. When prescribed off label, tigecycline prescriptions were associated with a higher mortality and incidence of side effects.
Conclusion: The tigecycline remains a valid option for the treatment of infections dues to multi-resistant bacteria especially when other alternatives are scarce or in cases of renal failure.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pharma.2020.10.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Radiosynthesis and Preclinical Evaluation of [Tc]Tc-Tigecycline Radiopharmaceutical to Diagnose Bacterial Infections.
Pharmaceuticals (Basel)
September 2024
Department of Chemistry, Government College University Faisalabad, Faisalabad 38040, Pakistan.
Background/objectives: As a primary source of mortality and disability, bacterial infections continue to develop a severe threat to humanity. Nuclear medicine imaging (NMI) is known for its promising potential to diagnose deep-seated bacterial infections. This work aims to develop a new technetium-99m (Tc) labeled tigecycline radiopharmaceutical as an infection imaging agent.
View Article and Find Full Text PDFReal-world safety profile of tetracyclines in children younger than 8 years old: an analysis of FAERS database and review of case report.
Expert Opin Drug Saf
July 2024
Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background: The study aims to obtain the real-world safety profile of tetracyclines in children younger than 8 years old and provide reference for clinical drug applications.
Research Design And Methods: We made a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database through OpenVigil 2 and conducted a review of case reports regarding adverse drug reactions (ADRs) of tetracyclines in children younger than 8-year-old.
Results: FAERS analysis identified 32 ADRs of tetracyclines in children younger than 8-year-old.
Real world drug treatment models for pregnancy complicated with urinary tract infection in China from 2018 to 2022: a cross-section analysis.
Front Pharmacol
January 2024
Department of Pharmacy, The Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
Urinary tract infection (UTI) is common in pregnant women. The selection of anti-infection plans during pregnancy must take into account the dual factors of patient pregnancy status and urinary tract infection anti-infection treatment, as well as the efficacy, cost, risk, and potential adverse reactions associated with each method applied to individual patients. Consequently, there are numerous drugs from which to choose; presently, there is no unified conclusion regarding the choice of drug therapy, and there is a lack of long-term drug treatment for UTI during pregnancy.
View Article and Find Full Text PDFHematological adverse events associated with anti-MRSA agents: a real-world analysis based on FAERS.
Expert Opin Drug Saf
October 2024
Department of Pharmacy, University Town Hospital, Chongqing Medical University, Chongqing, China.
This study investigated the patterns of hematological adverse events related to daptomycin (DAP), tigecycline (TIG), vancomycin (VAN) and linezolid (LIN) in the FDA Adverse Event Reporting System (FAERS). Adverse event associations were analyzed through calculating reporting odds ratio (ROR), proportional reporting ratio (PRR), multiple gamma Poisson shrinkage (MGPS), and Bayesian confidence propagation neural network (BCPNN). A comprehensive descriptive analysis was also conducted considering factors such as age, gender, daily dose, cumulative dose, and time to onset.
View Article and Find Full Text PDFMolecular epidemiology and antimicrobial resistance patterns of carbapenem-resistant isolates from patients admitted at ICUs of a teaching hospital in Zunyi, China.
Front Cell Infect Microbiol
December 2023
Department of Laboratory Medicine, The First People's Hospital of Zunyi (The Third Affiliated Hospital of Zunyi Medical University), Zunyi, China.
Background: Carbapenem-resistant (CRAB) has emerged as a predominant strain of healthcare-associated infections worldwide, particularly in intensive care units (ICUs). Therefore, it is imperative to study the molecular epidemiology of CRAB in the ICUs using multiple molecular typing methods to lay the foundation for the development of infection prevention and control strategies. This study aimed to determine the antimicrobial susceptibility profile, the molecular epidemiology and conduct homology analysis on CRAB strains isolated from ICUs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!